Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Novalead will study the effectiveness of an anti- parasitic drug in the recovery of moderately ill Covid-19 patients. Novalead is enrolling 100 patients across six centres for the trial which is expected to start in a month’s time.
Lead Product(s): Nitazoxanide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2020
Details:
According to the company, NLP21 shows promising ability to act on COVID-19 through multiple relevant targets which enables its not only to prevent virus binding to the human cells but also clear damaged human cells to allow regeneration of healthier cells.
Lead Product(s): NLP21
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020